Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation

A. Alvarez-Larrán, A. Pereira, P. Guglielmelli, JC. Hernández-Boluda, E. Arellano-Rodrigo, F. Ferrer-Marín, A. Samah, M. Griesshammer, A. Kerguelen, B. Andreasson, C. Burgaleta, J. Schwarz, V. García-Gutiérrez, R. Ayala, P. Barba, MT....

. 2016 ; 101 (8) : 926-31. [pub] 20160512

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17031742

The role of antiplatelet therapy as primary prophylaxis of thrombosis in low-risk essential thrombocythemia has not been studied in randomized clinical trials. We assessed the benefit/risk of low-dose aspirin in 433 patients with low-risk essential thrombocythemia (271 with a CALR mutation, 162 with a JAK2(V617F) mutation) who were on antiplatelet therapy or observation only. After a follow up of 2215 person-years free from cytoreduction, 25 thrombotic and 17 bleeding episodes were recorded. In CALR-mutated patients, antiplatelet therapy did not affect the risk of thrombosis but was associated with a higher incidence of bleeding (12.9 versus 1.8 episodes per 1000 patient-years, P=0.03). In JAK2(V617F)-mutated patients, low-dose aspirin was associated with a reduced incidence of venous thrombosis with no effect on the risk of bleeding. Coexistence of JAK2(V617F)-mutation and cardiovascular risk factors increased the risk of thrombosis, even after adjusting for treatment with low-dose aspirin (incidence rate ratio: 9.8; 95% confidence interval: 2.3-42.3; P=0.02). Time free from cytoreduction was significantly shorter in CALR-mutated patients with essential thrombocythemia than in JAK2(V617F)-mutated ones (median time 5 years and 9.8 years, respectively; P=0.0002) and cytoreduction was usually necessary to control extreme thrombocytosis. In conclusion, in patients with low-risk, CALR-mutated essential thrombocythemia, low-dose aspirin does not reduce the risk of thrombosis and may increase the risk of bleeding.

AOU Careggi and Department of Experimental and Clinical Medicine University of Florence Italy

Center for Research and Innovation of MPN

Centre for Cancer Research and Cell Biology Queen's University Belfast UK

Department of Clinical Science and Education Karolinska Institute South Hospital Stockholm Sweden

Department of Hematology VU University Medical Center Amsterdam The Netherlands

Division of Hematology University Hospital Basel Switzerland

Haematology Department Guys' and St Thomas' NHS Foundation Trust London UK

Hematology and Medical Oncology Department Hospital Morales Messeguer IMIB Arrixaca UCAM Murcia Spain

Hematology Department Hospital Clínic IDIBAPS Barcelona Spain

Hematology Department Hospital Clínico Valencia Spain

Hematology Department Hospital del Mar IMIM UAB Barcelona Spain

Hematology Department Hospital Dr Negrín Las Palmas de Gran Canaria Spain

Hematology Department Hospital La Paz Madrid Spain

Hematology Department Hospital Príncipe de Asturias Alcalá de Henares Spain

Hematology Department Hospital Ramón y Cajal Madrid Spain

Hematology Department Hospital Universitario 12 de Octubre Madrid Spain

Hematology Department Hospital Vall d'Hebron Barcelona Spain

Hematology Oncology and Palliative Care Johannes Wesling Academic Medical Center University of Hannover Teaching Hospital Germany

Hematology Section Uddevalla Hospital NU Hospital Group Sweden

Hematotherapy and Hemostasis Department Hospital Clínic Barcelona Spain

Institute of Hematology and Blood Transfusion Prague Czech Republic

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031742
003      
CZ-PrNML
005      
20171025125424.0
007      
ta
008      
171025s2016 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2016.146654 $2 doi
035    __
$a (PubMed)27175028
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Alvarez-Larrán, Alberto $u Hematology Department, Hospital del Mar, IMIM, UAB, Barcelona, Spain 95967@parcdesalutmar.cat. $7 gn_A_00005121
245    10
$a Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation / $c A. Alvarez-Larrán, A. Pereira, P. Guglielmelli, JC. Hernández-Boluda, E. Arellano-Rodrigo, F. Ferrer-Marín, A. Samah, M. Griesshammer, A. Kerguelen, B. Andreasson, C. Burgaleta, J. Schwarz, V. García-Gutiérrez, R. Ayala, P. Barba, MT. Gómez-Casares, C. Paoli, B. Drexler, S. Zweegman, MF. McMullin, J. Samuelsson, C. Harrison, F. Cervantes, AM. Vannucchi, C. Besses,
520    9_
$a The role of antiplatelet therapy as primary prophylaxis of thrombosis in low-risk essential thrombocythemia has not been studied in randomized clinical trials. We assessed the benefit/risk of low-dose aspirin in 433 patients with low-risk essential thrombocythemia (271 with a CALR mutation, 162 with a JAK2(V617F) mutation) who were on antiplatelet therapy or observation only. After a follow up of 2215 person-years free from cytoreduction, 25 thrombotic and 17 bleeding episodes were recorded. In CALR-mutated patients, antiplatelet therapy did not affect the risk of thrombosis but was associated with a higher incidence of bleeding (12.9 versus 1.8 episodes per 1000 patient-years, P=0.03). In JAK2(V617F)-mutated patients, low-dose aspirin was associated with a reduced incidence of venous thrombosis with no effect on the risk of bleeding. Coexistence of JAK2(V617F)-mutation and cardiovascular risk factors increased the risk of thrombosis, even after adjusting for treatment with low-dose aspirin (incidence rate ratio: 9.8; 95% confidence interval: 2.3-42.3; P=0.02). Time free from cytoreduction was significantly shorter in CALR-mutated patients with essential thrombocythemia than in JAK2(V617F)-mutated ones (median time 5 years and 9.8 years, respectively; P=0.0002) and cytoreduction was usually necessary to control extreme thrombocytosis. In conclusion, in patients with low-risk, CALR-mutated essential thrombocythemia, low-dose aspirin does not reduce the risk of thrombosis and may increase the risk of bleeding.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a kalretikulin $x genetika $7 D037282
650    _2
$a dítě $7 D002648
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a krvácení $x epidemiologie $x etiologie $7 D006470
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a Janus kinasa 2 $x genetika $7 D053614
650    _2
$a počet leukocytů $7 D007958
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a mutace $7 D009154
650    _2
$a fenotyp $7 D010641
650    _2
$a inhibitory agregace trombocytů $x terapeutické užití $7 D010975
650    _2
$a esenciální trombocytemie $x komplikace $x diagnóza $x genetika $7 D013920
650    _2
$a trombóza $x epidemiologie $x etiologie $x prevence a kontrola $7 D013927
650    _2
$a čas zasáhnout při rozvinutí nemoci $7 D061665
650    _2
$a výsledek terapie $7 D016896
650    12
$a pozorné vyčkávání $7 D057832
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pereira, Arturo $u Hematotherapy and Hemostasis Department, Hospital Clínic, Barcelona, Spain.
700    1_
$a Guglielmelli, Paola $u Center for Research and Innovation of MPN (CRIMM); AOU Careggi, and Department of Experimental and Clinical Medicine, University of Florence, Italy.
700    1_
$a Hernández-Boluda, Juan Carlos $u Hematology Department, Hospital Clínico, Valencia, Spain.
700    1_
$a Arellano-Rodrigo, Eduardo $u Hematotherapy and Hemostasis Department, Hospital Clínic, Barcelona, Spain. $7 gn_A_00008207
700    1_
$a Ferrer-Marín, Francisca $u Hematology and Medical Oncology Department, Hospital Morales Messeguer, IMIB-Arrixaca, UCAM, Murcia, Spain.
700    1_
$a Samah, Alimam $u Haematology Department, Guys' and St Thomas' NHS Foundation Trust, London, UK.
700    1_
$a Griesshammer, Martin $u Hematology, Oncology & Palliative Care, Johannes Wesling Academic Medical Center, University of Hannover Teaching Hospital, Germany.
700    1_
$a Kerguelen, Ana $u Hematology Department, Hospital La Paz, Madrid, Spain.
700    1_
$a Andreasson, Bjorn $u Hematology Section, Uddevalla Hospital, NU Hospital Group, Sweden. $7 gn_A_00006418
700    1_
$a Burgaleta, Carmen $u Hematology Department, Hospital Príncipe de Asturias, Alcalá de Henares, Spain.
700    1_
$a Schwarz, Jiri $u Institute of Hematology & Blood Transfusion, Prague, Czech Republic.
700    1_
$a García-Gutiérrez, Valentín $u Hematology Department, Hospital Ramón y Cajal, Madrid, Spain.
700    1_
$a Ayala, Rosa $u Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain. $7 gn_A_00010522
700    1_
$a Barba, Pere $u Hematology Department, Hospital Vall d'Hebron, Barcelona, Spain.
700    1_
$a Gómez-Casares, María Teresa $u Hematology Department, Hospital Dr. Negrín, Las Palmas de Gran Canaria, Spain.
700    1_
$a Paoli, Chiara $u Center for Research and Innovation of MPN (CRIMM); AOU Careggi, and Department of Experimental and Clinical Medicine, University of Florence, Italy.
700    1_
$a Drexler, Beatrice $u Division of Hematology, University Hospital Basel, Switzerland.
700    1_
$a Zweegman, Sonja $u Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
700    1_
$a McMullin, Mary F $u Centre for Cancer Research and Cell Biology, Queen's University, Belfast, UK.
700    1_
$a Samuelsson, Jan $u Department of Clinical Science and Education, Karolinska Institute, South Hospital, Stockholm, Sweden.
700    1_
$a Harrison, Claire $u Haematology Department, Guys' and St Thomas' NHS Foundation Trust, London, UK.
700    1_
$a Cervantes, Francisco $u Hematology Department, Hospital Clínic, IDIBAPS, Barcelona, Spain.
700    1_
$a Vannucchi, Alessandro M $u Center for Research and Innovation of MPN (CRIMM); AOU Careggi, and Department of Experimental and Clinical Medicine, University of Florence, Italy.
700    1_
$a Besses, Carlos $u Hematology Department, Hospital del Mar, IMIM, UAB, Barcelona, Spain.
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 101, č. 8 (2016), s. 926-31
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27175028 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171025125507 $b ABA008
999    __
$a ok $b bmc $g 1255335 $s 992769
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 101 $c 8 $d 926-31 $e 20160512 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20171025

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace